Tumor Suppressor and Targeted Therapy in Hepatocellular Carcinoma: From Diagnosis to Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 2034
Special Issue Editors
Interests: liver cancer; viral hepatitis; fatty liver; liver cirrhosis
Special Issues, Collections and Topics in MDPI journals
2. Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
Interests: hepatology; liver cancer; liver tumor biopsy and ablation; contrast ultrasound
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The carcinogenesis of HCC is a complex process that is associated with the aberrant activation of various cellular and molecular pathways and the disruption of balance between the activation and inactivation of protooncogenes and tumor suppressor genes, respectively. During the past few decades, advancements in molecular cell biology have improved our understanding of the detailed molecular mechanisms underlying tumor initiation and progression‚ contributing to the evolution of strategies for prevention, surveillance, early diagnosis, and treatment. At present, many clinical trials that examine the use of molecular-targeted therapies that inhibit the growth of tumor cells by interfering with the molecular mechanisms of HCC carcinogenesis have shown promising results. In this Special Issue of Cancers, we will include original or review articles concerning “tumor suppressor” or “targeted therapy” in hepatocellular carcinoma. The Editor and Co-editors will monitor and select the best articles regarding subjects such as clinical screening, genetic testing, diagnosis, treatments, and the prevention of complications in patients with hepatocellular carcinoma.
Prof. Dr. Ching-Sheng Hsu
Dr. Po-Heng Chuang
Dr. I-Cheng Lee
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor suppressor
- targeted therapy
- hepatocellular carcinoma
- human
- diagnosis
- surveillance
- complication
- early detection
- carcinogenesis
